Cargando…

MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients

PURPOSE: The prognostic factors for diffuse large B‐cell lymphoma (DLBCL) have been fully explored, but prognostic information for bulky mass DLBCL patients is limited. This study aimed to analyze the prognostic value of MYC protein expression and other biological parameters in bulky mass DLBCL pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yanjie, Liu, Donglin, Zhang, Xudong, Zhang, Mingzhi, Li, Shenglei, Feng, Xiaoyan, Dong, Meng, Ma, Shanshan, Qian, Siyu, Wang, Zeyuan, Zhang, Yue, Wang, Pengyuan, Mei, Shuhao, Chen, Qingjiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557898/ https://www.ncbi.nlm.nih.gov/pubmed/37641492 http://dx.doi.org/10.1002/cam4.6463

Ejemplares similares

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification
por: Miyaoka, Masashi, et al.
Publicado: (2022)

Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type
por: Wang, Jing-hua, et al.
Publicado: (2017)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
por: Wawire, Jonathan, et al.
Publicado: (2019)

R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2
por: Sun, Peng, et al.
Publicado: (2021)

High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival
por: Yi, Shuhua, et al.
Publicado: (2015)

Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis
por: Li, Lu, et al.
Publicado: (2018)

Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma
por: Zhang, YunXiang, et al.
Publicado: (2019)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Co-overexpression of bcl-2 and c-myc in uterine cervix carcinomas and premalignant lesions
por: Protrka, Z., et al.
Publicado: (2011)

Double‑hit primary lymphoma (MYC and BCL2) in the bilateral ovary: A case report
por: Zhang, Yan, et al.
Publicado: (2023)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma
por: Liu, Xiaoqian, et al.
Publicado: (2022)

MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma
por: Lu, Ting-Xun, et al.
Publicado: (2015)

Upregulation of fatty acid synthase in MYC and BCL-2 double-expressor lymphoma
por: Zhong, Xing, et al.
Publicado: (2021)

Immunohistochemistry for c‐myc and bcl‐2 overexpression improves risk stratification in primary central nervous system lymphoma
por: Hatzl, Stefan, et al.
Publicado: (2020)

Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma
por: Wang, Jing, et al.
Publicado: (2015)

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
por: Witte, Hanno M., et al.
Publicado: (2023)

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
por: Ye, Qing, et al.
Publicado: (2015)

A Selective Small‐Molecule c‐Myc Degrader Potently Regresses Lethal c‐Myc Overexpressing Tumors
por: Xu, Ying, et al.
Publicado: (2022)

MYC/BCL2 double- and MYC/BCL2/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)
por: Takeoka, Kayo, et al.
Publicado: (2022)

Generation of a Murine Model for c-MYC and BCL2 Co-expression B Cell Lymphomas
por: Cai, Zhenming, et al.
Publicado: (2020)

MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2014)

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphoma
por: Kawamoto, Keisuke, et al.
Publicado: (2016)

MYC overexpression with its prognostic and clinicopathological significance in breast cancer
por: Qu, Jingkun, et al.
Publicado: (2017)

Correction: MYC Expression in Concert With BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2018)

MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding sites
por: See, Yi Xiang, et al.
Publicado: (2022)

C-MYC and BCL-2 mediate YAP-regulated tumorigenesis in OSCC
por: Chen, Xiyan, et al.
Publicado: (2017)

Overexpression of SmMYC2 Increases the Production of Phenolic Acids in Salvia miltiorrhiza
por: Yang, Na, et al.
Publicado: (2017)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment
por: Singh, Aditi, et al.
Publicado: (2022)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
por: Mo, W., et al.
Publicado: (2022)

BCL-W makes only minor contributions to MYC-driven lymphoma development
por: Diepstraten, Sarah T., et al.
Publicado: (2023)

Double-hit lymphoma (rearrangements of MYC, BCL-2) during pregnancy: A case report
por: Xie, Fan, et al.
Publicado: (2021)

BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase
por: Zou, Dehui, et al.
Publicado: (2017)

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study
por: Ma, Qianwen, et al.
Publicado: (2019)

Correction: MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Publicado: (2014)

High‐grade B‐cell lymphoma with MYC and BCL2 rearrangements with abundant multinucleated giant tumor cells
por: Zhang, Man, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a1jumhahlnt3atfgs9asc6lkgq